Compare Heron Therapeutics Inc (HRTX) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Occidental Petroleum Corporation — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Occidental Petroleum Corporation trades at $59.81 (market cap $58.19B). The key difference: Occidental Petroleum Corporation is far larger — about 855.6× Heron Therapeutics Inc's market cap, and Occidental Petroleum Corporation pays a 1.92% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Occidental Petroleum Corporation for 92 Days on average.
| HRTX | OXY | |
|---|---|---|
Market Cap | $68.01M | $58.19B |
Volume | 1,891,941 | 7,092,290 |
Sector | Health | Energy |
52-Week High | $1.49 | $66.24 |
52-Week Low | $0.27 | $38.92 |
Typical Hold Time | 35 Days | 92 Days |
Enterprise Value | $174.75M | $76.95B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Occidental Petroleum (OXY) trades at $58.21, down 0.21% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a 30.32% net income margin and 21.46% ROE, while valuation metrics appear reasonable with a P/E of 17.17 and EV/EBITDA of 5.42. Recent earnings have consistently beaten expectations, and the company maintains a solid balance sheet with $2.13 billion in cash. Analyst consensus is bullish with a $71.40 price target, and the upcoming Q3 2026 earnings report on November 9 is a key catalyst.
OXY presents a compelling investment case with strong fundamentals, reasonable valuation, and positive analyst sentiment. The primary opportunities include continued earnings outperformance, debt reduction progress, and carbon management initiatives. Key risks include oil price volatility, declining revenue trends from $36.6B in 2022 to $21.6B in 2025, and execution challenges in the competitive energy sector. The stock offers upside potential to analyst targets but remains sensitive to commodity price movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
